AbstAbstract
Introduction
Gaucher disease is a metabolic autosomal recessive transmitted disease that occurs due to mutations in a gene located on chromosome 
Presenting the case
We present the case of a 34-year-old female 
Clinical cases

Image no. 2 Gaucher disease: Düsseldorf score 8, the severity class of bone marrow infiltration IIa. Bone MRI: sections in the coronary femur area T2 (A, B, C), T1 (D, E, F) and STIR (G, H, I); small, focal, inframillimetric areas, slightly hyposignal T1-hypersignal T2; bilateral intramedular STIR hypersignal with a non-homogeneous contrast setting; femoral diaphysis deformation (1/2 distal) Erlenmeyer balloon type, with cortical integrity.
Internal 
Discussions -conclusions
When the patient was presented we discussed and excluded outcomes and conditions that evolve with hepato-splenomegaly, anaemia and thrombocytopenia. In this case, the (3) average duration from the first signs and symptoms until the diagnosis was 144 months, the patient first consulted with three different specialists (family physician, internist, surgeon). Splenomegaly is present in 9 0 % o f p a t i e n t s , a n d a n a e m i a , thrombocytopenia and, to a lesser extent, leukopenia can be observed simultaneously or independently of each other. In this case, (4, 5) the anaemia, thrombocytopenia and leukopenia were present at the same time. (6) musculoskeletal manifestations in Gaucher disease do not correlate with the severity of the disease, they significantly contribute to morbidity and disability. Necrosis of femoral (7) heads, femoral condyles or femoral plateaus are typical bone lesions in Gaucher disease.
Acute pain (bone crisis), signs of local inflammation and fever may suggest an infection. These can take several days or weeks. Radiographies after stabilization of lesions may reveal avascular necrosis or bone infarction. Enzyme replacement therapy (8) virtually eliminated the need for splenectomy, which is associated with pulmonary hypertension, sepsis, advanced liver disease, and rapid progression of bone disease. (9) Enzymatic substitution treatment cannot reverse hepatic, splenic, or medullar fibrosis.
Thus, early treatment is important before the development of irreversible complications. (10) The result rates for the therapeutic target may vary depending on the organ or system.
Visceral and haematological compartments may begin to respond within 12 months of treatment, achieving the therapeutic target between 12 and 36 months. 
